Plasma cell leukaemia presenting as flower-shaped plasma cells mimicking adult T-cell leukaemia or lymphoma

Publication date: March 2020Source: The Lancet Haematology, Volume 7, Issue 3Author(s): Motoharu Shibusawa
Source: The Lancet Haematology - Category: Hematology Source Type: research

Related Links:

CONCLUSION: This preliminary investigation in Iran shows that the main EBV genotype into our region probably is genotype I (91.2%) which it is similar to others. We could not find any statistically significant association between the virus infection and viral load with any specific disease and patients' demographic data. . PMID: 32212795 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
AbstractBackgroundSALL4 is a zinc finger transcription factor that exerts its physiological role during embryo-fetal development. Analyses of SALL4 expression have shown its oncogenic role in precursor B-cell lymphoblastic lymphoma, acute and chronic myeloid leukemia, gastrointestinal, breast, and lung cancers. The aim of this study was to determine the immunohistochemical profile of SALL4 in pediatric yolk sac tumors (YSTs).Methods and resultsImmunohistochemistry detection of SALL4 was performed in 22 cases of pediatric YSTs and 10 mature teratomas. The percentage of tumor cells stained was scored as 0, 1+  (1&ndas...
Source: Pediatric Surgery International - Category: Surgery Source Type: research
Conditions:   Non Hodgkin Lymphoma;   Acute Lymphoblastic Leukemia;   Diffuse Large B Cell Lymphoma;   Primary Mediastinal Large B Cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma Interventions:   Drug: TC-110 T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide Sponsor:   TCR2 Therapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   T-Lymphoblastic Lymphoma/Leukemia Intervention:   Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Precursor B-cell lymphoblastic lymphoma (PBLL) is a rare subtype of non-Hodgkin lymphoma originating from B-cell precursors. PBLL, as a solitary mass lesion affecting the central nervous system without leukemic disease at presentation, is quite uncommon. Here we report a rare PBLL case with Philadelphia chromosome positivity. The 44-year-old male presented a solitary bulky mass primarily involving the left frontotemporal lobes and extended into the infratemporal fossa. Pretreatment PET/CT imaging showed avid 18F-fluorodeoxyglucose (18F-FDG) uptake of the lesion. By aggressive chemotherapy and imatinib maintenance treatment...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: With up to 8 years of follow-up, sustained responses and long-term tolerability of single-agent ibrutinib were observed with treatment of first-line or relapsed/refractory CLL/SLL, including high-risk CLL/SLL. PMID: 32209572 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
keshima Yoko Aida Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leucosis. However, less than 5% of BLV-infected cattle will develop lymphoma, suggesting that, in addition to viral infection, host genetic polymorphisms might play a role in disease susceptibility. Bovine leukocyte antigen (BoLA)-DRB3 is a highly polymorphic gene associated with BLV proviral load (PVL) susceptibility. Due to the fact that PVL is positively associated with disease progression, it is believed that controlling PVL can prevent lymphoma development. Thus, many studies have focused on the relationship between PVL and B...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Publication date: Available online 21 March 2020Source: Cancer GeneticsAuthor(s): Yassmine Akkari, Helene Bruyere, Tanner R. Hagelstrom, Rashmi Kanagal-Shamanna, Jie Liu, Minjie Luo, Fady M. Mikhail, Beth Pitel, Gordana Raca, Mary Shago, Lina Shao, Lisa R. Smith, Teresa A. Smolarek, Ashwini Yenamandra, Linda B. Baughn
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
More News: Hematology | Leukemia | Lymphoma